Citigroup Forecasts Strong Price Appreciation for Sensei Biotherapeutics (NASDAQ:FTH) Stock

Key Points

• Citigroup raised its Sensei Biotherapeutics price target from $55 to $60 and maintained a Buy rating, implying 388.76% upside from the prior close.
• Analyst sentiment is broadly positive: the stock has a consensus “Moderate Buy” rating and an average price target of $56.58, though one analyst rates it Hold and one Sell.
• Shares traded at $12.28, while the company reported a quarterly loss of $0.79 per share—worse than analysts’ expected loss of $0.66.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) had its price objective lifted by investment analysts at Citigroup from $55.00 to $60.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a "buy" rating on the stock. Citigroup's target price would indicate a potential upside of 388.76% from the company's previous close.

FTH has been the topic of several other research reports. Citizens Jmp began coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They set an "outperform" rating and a $51.00 price target on the stock. Guggenheim lowered their target price on Sensei Biotherapeutics from $70.00 to $69.00 and set a "buy" rating for the company in a report on Wednesday, November 4th. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. JonesTrading assumed coverage on shares of Sensei Biotherapeutics in a report on Tuesday, August 4th. They issued a "buy" rating and a $55.00 price target on the stock. Finally, William Blair assumed coverage on shares of Sensei Biotherapeutics in a report on Friday, October 16th. They set an "outperform" rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $56.58.

Sensei Biotherapeutics Stock Performance

FTH stock traded down $0.40 on Tuesday, reaching $12.28. 858,135 shares of the company traded hands, compared to its average volume of 274,071. The firm's fifty day simple moving average is $27.04. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $42.14. The company has a market cap of $317.21 million, a P/E ratio of -0.09 and a beta of -0.15.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.13). As a group, sell-side analysts forecast that Sensei Biotherapeutics will post -13.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sensei Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FTH. Candriam S.C.A. purchased a new stake in shares of Sensei Biotherapeutics during the 3rd quarter worth $9,542,000. State of Wyoming acquired a new position in Sensei Biotherapeutics in the third quarter valued at $25,000. China Universal Asset Management Co. Ltd. lifted its position in Sensei Biotherapeutics by 48.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,360 shares of the company's stock valued at $150,000 after buying an additional 1,760 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Sensei Biotherapeutics during the 2nd quarter valued at about $307,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Sensei Biotherapeutics during the 2nd quarter valued at $3,610,000. Hedge funds and other institutional investors own 10.50% of the company's stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body's immune system recognize and attack cancer cells. The company's publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.